Senior Principal Scientist, ADC Oncology Discovery Biology at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, BiotechnologyIndustries

Requirements

Experience leading antibody-drug conjugate (ADC) drug discovery teams from target concept to IND filing
Experience discovering novel linker-payloads beyond traditional cytotoxic linkers (preferred)
Creative scientist leader capable of working across highly matrixed teams to advance drug discovery programs
Highly motivated and collaborative
Dedicated to leading matrixed ADC discovery project teams from early stages/target concept through to IND filing

Responsibilities

Lead innovative ADC projects from concept to clinic, leveraging proprietary technologies
Shape scientific strategy and mentor rising talent
Contribute to the next wave of ADC innovation as a member of the Discovery Biology ADC Team
Lead a team of scientists to deliver biology studies supporting ADC candidate discovery and characterization
Collaborate with bioinformaticians and translational research scientists
Work with leadership and across the company to advance drug discovery programs from early stages to IND filing

Skills

ADC

Oncology Discovery

Cancer Biology

Immuno-oncology

In Vitro Models

In Vivo Models

Ex Vivo Models

Biomarkers

Translational Medicine

Cell Therapy

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free